A multigene array for measurable residual disease detection in AML patients undergoing SCT

Bone Marrow Transplantation

Volumn 50, Issue 5, 2015, Pages 642-651

  Goswami, M ^a   McGowan, K S ^a   Lu, K ^a   Jain, N ^a   Candia, J ^b,c   Hensel, N F ^a   Tang, J ^a   Calvo, K R ^d   Battiwalla, M ^a   Barrett, A J ^a   Hourigan, C S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Bldg 142   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WT1 PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIGENE FAMILY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; ADOLESCENT; ALLOGRAFT; BLOOD; CHILD; CLINICAL TRIAL; INFANT; LEUKEMIA, MYELOID, ACUTE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROCEDURES; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ALLOGRAFTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION;

EID: 84928926330     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.326     Document Type: Article

References (62)

1. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
2. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
3. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617-1628.
4. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605-1616.
5. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
6. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
7. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
8. Kroger N, Bacher U, Bader P, Bottcher S, Borowitz MJ, Dreger P et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010; 16: 1187-1211.
9. Wayne AS, Giralt S, Kroger N, Bishop MR. Proceedings from the National Cancer Institute's Second International Workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: introduction. Biol Blood Marrow Transplant 2013; 19: 1534-1536.
10. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27: 1229-1235.
11. Bacher U, Talano JA, Bishop MR. Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant 2012; 18: S62-S73.
12. Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 2010; 3: 429-441.
13. Goldman JM, Gale RP. What does MRD in leukemia really mean Leukemia 2014; 28: 1131.
14. Appelbaum FR. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Pract Res Clin Haematol 2013; 26: 279-284.
15. Carlson KS, Guzman ML. Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia Curr Hematol Malig Rep 2013; 8: 109-115.
16. Ossenkoppele G, Schuurhuis GJ. MRD in AML: time for redefinition of CR Blood 2013; 121: 2166-2168.
17. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program 2012; 2012: 35-42.
18. Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 2011; 117: 2577-2584.
19. Hokland P, Ommen HB, Nyvold CG, Roug AS. Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission-methodologies in relation to their clinical situation. Br J Haematol 2012; 158: 569-580.
20. Buckley SA, Appelbaum FR, Walter RB. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 2013; 48: 630-641.
21. Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122: 1813-1821.
22. Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013; 121: 2213-2223.
23. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012; 120: 2826-2835.
24. Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013; 121: 4056-4062.
25. Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013; 10: 460-471.
26. Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a "moving target" for detection of residual disease. Cytometry 2014; 86: 3-14.
27. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27: 5195-5201.
28. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 2004; 125: 590-600.
29. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405-1412.
30. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405-409.
31. Pozzi S, Geroldi S, Tedone E, Luchetti S, Grasso R, Colombo N et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013; 160: 503-509.
32. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008; 141: 782-791.
33. Rossi G, Carella AM, Minervini MM, Savino L, Fontana A, Pellegrini F et al. Minimal residual disease after allogeneic stem cell transplantation: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (complete chimerism versus low level mixed chimerism) in acute leukemia. Leuk Lymphoma 2013; 54: 2660-2666.
34. Kwon M, Martinez-Laperche C, Infante M, Carretero F, Balsalobre P, Serrano D et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant 2012; 18: 1235-1242.
35. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698-1704.
36. Zhao XS, Yan CH, Liu DH, Xu LP, Liu YR, Liu KY et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol 2013; 92: 1111-1119.
37. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115-2121.
38. Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011; 25: 498-505.
39. Zhao XS, Jin S, Zhu HH, Xu LP, Liu DH, Chen H et al. Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47: 499-507.
40. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31: 3889-3897.
41. Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 2014; 29: 137-144.
42. Miyazaki T, Fujita H, Fujimaki K, Hosoyama T, Watanabe R, Tachibana T et al. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res 2012; 36: 998-1003.
43. Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120: 468-472.
44. Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012; 30: 3625-3632.
45. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-552.
46. Jaso JM, Wang SA, Jorgensen JL, Lin P. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant 2014; 49: 1129-1138.
47. Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI et al. Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia 2014; 28: 1167-1170.
48. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2012; 10: 984-1021.
49. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 1947; 12: 153-157.
50. Vergara IA, Norambuena T, Ferrada E, Slater AW, Melo F. StAR: a simple tool for the statistical comparison of ROC curves. BMC Bioinformatics 2008; 9: 265.
51. Hourigan CS, Levitsky HI. Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J 2011; 17: 309-324.
52. Rossi G, Carella AM, Minervini MM, Savino L, Fontana A, Pellegrini F et al. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia. Leuk Lymphoma 2013; 54: 2660-2666.
53. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stemcell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730-3738.
54. Candia J, Maunu R, Driscoll M, Biancotto A, Dagur P, McCoy JP Jr. et al. From cellular characteristics to disease diagnosis: uncovering phenotypes with supercells. PLoS Comput Biol 2013; 9: e1003215.
55. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia- A Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
56. Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011; 29: 2709-2716.
57. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333.
58. Hourigan CS. Next Generation MRD. Biol Blood Marrow Transplant 2014; 20: 1259-1260.
59. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3256-3262.
60. Hourigan CS, McCarthy P, de Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 154-163.
61. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381-389.
62. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res 2007; 67: 9055-9065.